NIAID participates in or funds many different consortia, clinical trial programs, networks, and research collaborations that help to move science forward. These are listed here, with new ones added all the time. Use the Search for Programs or Networks field to narrow your search.
Showing results filtered by:
Search Results
26 ResultsAccessing Clinical Data
AccessClinicalData@NIAID is a cloud-based, secure data platform that enables sharing of and access to reports and data sets from NIAID COVID-19 and other sponsored clinical trials for the basic and clinical research community.
Antibacterial Resistance Leadership Group (ARLG)
ARLG is a major clinical effort to address antibacterial resistance (AR) including collaborations in 19 countries and over 40 clinical research studies involving more than 20,000 volunteers. Studies include clinical testing of new drugs to treat multidrug-resistant Gram-negative bacteria, evaluating diagnostic devices in clinical settings, and optimizing treatment regimens to reduce the emergence of resistance. In 2019, NIAID renewed the program’s funding, providing up to $102.5 million over 7 years.
Antiviral Drug Discovery (AViDD) Centers for Pathogens of Pandemic Concern
The AViDD Centers will conduct innovative, multidisciplinary research to develop candidate COVID-19 antivirals, especially those that can be taken in an outpatient setting, as well as antivirals targeting specific viral families with high potential to cause a pandemic in the future.
Biocontainment Research Facilities
An overview of the NIAID Biocontainment Laboratories including major focus areas and contact information.
Bioinformatics Resource Centers for Infectious Diseases Program
The Bioinformatics Resource Centers (BRCs) for Infectious Diseases program was initiated in 2004 with the main objective of providing public access to computational platforms and analysis tools that enable collecting, archiving, updating, and integrating a variety of genomics and related research data relevant to infectious diseases, and pathogens and their interaction with hosts.
Centers for Research in Emerging Infectious Diseases (CREID)
An overview of the NIAID Centers for Research in Emerging Infectious Diseases (CREID) including contact information and major focus areas.
Centers for Research on Structural Biology of Infectious Diseases (CRSTAL-ID)
The NIAID Structural Genomics Centers for Infectious Diseases use state-of-the-art technologies to characterize the 3-D structure of proteins.
Centers of Excellence for Influenza Research and Response (CEIRR)
NIAID established the Centers of Excellence for Influenza Research and Response (CEIRR) to study natural history, transmission, and pathogenesis of influenza and provide an international research infrastructure to address influenza outbreaks.
Centers of Excellence for Translational Research (CETR)
NIAID-supported translational activities range from very early discovery-based efforts to late-stage preclinical development.
Collaborative Influenza Vaccine Innovation Centers (CIVICs)
NIAID CIVICs is a network of research centers that work together to develop more durable, broadly protective and longer-lasting influenza vaccines.
Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X)
The Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator global partnership was created by NIAID to address antibiotic resistance.
Combating Antibiotic-Resistant Bacteria Interdisciplinary Research Units (CARBIRU)
The Combating Antibiotic-Resistant Bacteria Interdisciplinary Research Units (CARBIRUs) are multidisciplinary research centers focused on bacterial pathogens for which antibiotic resistance poses a significant public health concern, as designated by the CDC’s 2019 Report on Antibiotic Resistance Threats in the United States. Each center brings together investigators from multiple disciplines to investigate non-antibiotic alternative treatment and preventive strategies, including bacteriophage, monoclonal antibodies, ligand mimetics, and defined microbial consortia; poorly understood resistance mechanisms contributing to bacterial persistence and antibiotic treatment failure; and identification and validation of novel bacterial targets for antibiotic intervention.
FEND for TB
The Feasibility of Novel Diagnostics for TB in Endemic Countries (FEND for TB) program supports the evaluation of early-stage diagnostics and novel diagnostic strategies for TB to address an urgent need for improved diagnostics.
Genomic Centers for Infectious Diseases (GCID)
The NIAID Genomic Centers for Infectious Diseases (GCID) provide insights into the biology of microbes, their role in pathogenesis, and their interactions with the host, including the microbiome, by supporting a diverse set of genomic capabilities, such as high-throughput sequencing and related genomic technologies.
Global Vaccine and Immunization Research Forum
The Global Vaccine and Immunization Research Forum (GVIRF) is a collaboration between NIAID, the Bill & Melinda Gates Foundation, and the World Health Organization. GVIRF brings together the entire vaccine and immunization research community biennially to evaluate progress in research objectives of the GVAP.
Immune Mechanisms of Protection Against Mycobacterium tuberculosis Centers (IMPAc-TB)
The Immune Mechanisms of Protection Against Mycobacterium tuberculosis Centers program is an initiative established by NIAID in 2019 to elucidate the immune responses needed to protect against infection with Mycobacterium tuberculosis (Mtb).
Infectious Diseases Clinical Research Consortium (IDCRC)
The consortium consists of the Vaccine and Treatment Evaluation Units (VTEUs) located across the US to conduct Phase 1 through 4 vaccine and treatment trials, including clinical studies in collaboration with industry partners. In addition, a consortium leadership group has been established that will include VTEU investigators as well as scientific experts in infectious diseases that will prioritize candidate vaccines, diagnostics, therapeutics and other interventions to test in clinical trials.
International Centers of Excellence for Malaria Research (ICEMR)
The ICEMRS are a global network of independent research centers in malaria-endemic settings, established by NIAID to provide the knowledge, tools, and evidence-based strategies crucial to understanding, controlling, and, ultimately, preventing malaria.
Research and Development of Vaccines and Monoclonal Antibodies for Pandemic Preparedness (ReVAMPP)
An overview of the Research and Development of Vaccines and Monoclonal Antibodies for Pandemic Preparedness (ReVAMPP) including contact information and major focus areas.
SARS-CoV-2 Assessment of Viral Evolution (SAVE) Program
The SARS-CoV-2 Interagency Group (SIG), established by the U.S. Department of Health and Human Services (HHS), works to rapidly characterize emerging variants and actively monitors their potential impact on SARS-CoV-2 vaccines, therapeutics, and diagnostics.
Systems Biology Consortium for Infectious Diseases
The NIAID/Division of Microbiology and Infectious Diseases (DMID) Systems Biology Consortium for Infectious Diseases is a group of interdisciplinary scientists that bridge disparate scientific disciplines including microbiology, immunology, infectious diseases, microbiome, mathematics, physics, bioinformatics, computational biology, machine learning, statistical methods, and mathematical modeli
Trans-NIH Microbiome Working Group (TMWG)
The Trans-NIH Microbiome Working Group (TMWG) was established to provide a forum for coordinating NIH extramural research activities related to the human microbiome.
Transatlantic Task Force on Antimicrobial Resistance (TATFAR)
TATFAR was created in 2009 to address the urgent threat of antimicrobial resistance (AMR). TATFAR’s technical experts from Canada, the European Union (EU), Norway, the United Kingdom, and the United States collaborate and share best practices to strengthen domestic and global efforts to combat AMR.
Tropical Medicine Research Centers (TMRCs)
NIAID established the Tropical Medicine Research Centers (TMRC) program in 1991 to fund NTD research centers in disease-endemic countries. The centers are designed to conduct research on the cause, diagnosis, prevention, and treatment of NTDs, and to build in-country research capacity. The program has increased capacity of local TMRC awardees to support independent research activities, conduct future clinical trials, and implement new treatment, prevention, and vector control strategies.
Tuberculosis Research Advancement Centers (TRACs)
TRACs will provide scientific leadership and institutional infrastructure dedicated to Tuberculosis research and will foster and enhance multidisciplinary collaboration. The Centers are dedicated to developing the next generation of scientific leaders in TB research.